Extended Data Fig. 4: Impact of smoking status, histology, stage, MPR and pCR on EFS. | Nature Medicine

Extended Data Fig. 4: Impact of smoking status, histology, stage, MPR and pCR on EFS.

From: Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Extended Data Fig. 4

a-c, Kaplan-Meier curves of EFS by smoking status (n = 22) (a), histology (n = 22) (b), and stage (n = 22) (c) in Nivo+CT arm. d-e, Kaplan-Meier curves of EFS by MPR (n = 22) (d) and pCR (n = 22) (e) using landmark analysis from the surgery date in Nivo+CT arm. f-h, Kaplan-Meier curves of EFS by smoking status (n = 22) (f), histology (n = 22) (g), and stage (n = 22) (h) in Ipi+Nivo+CT arm. *One patient died from SARS-CoV-2 infection-related complications (non-treatment related). i-j, Kaplan-Meier curves of EFS by MPR (n = 20) (i) and pCR (n = 20) (j) using landmark analysis from the surgery date in Ipi+Nivo+CT arm. Two-sided P values are from logrank test. ITT, intention-to-treat population; Nivo, nivolumab; Ipi, ipilimumab; CT, chemotherapy; EFS, event-free survival; Squamous, squamous cell carcinoma; Nonsquamous includes adenocarcinoma, carcinoma with neuroendocrine features, NOS NSCLC, sarcomatoid carcinoma, and large cell carcinoma; Never, never smoker; Former, former smoker; Former/Current, former/current smoker; MPR, major pathologic response; pCR, pathologic complete response.

Back to article page